Department of Bioengineering, Faculty of Enginering, Marmara University, Istanbul, 34722, Turkey.
Institute of Nanotechnology and Biotechnology, Istanbul Univeristy-Cerrahpasa, Istanbul, 34500, Turkey.
Macromol Biosci. 2024 Oct;24(10):e2400343. doi: 10.1002/mabi.202400343. Epub 2024 Sep 2.
Cancer is anticipated to become the pioneer reason of disease-related deaths worldwide in the next two decades, underscoring the urgent need for personalized and adaptive treatment strategies. These strategies are crucial due to the high variability in drug efficacy and the tendency of cancer cells to develop resistance. This study investigates the potential of theranostic nanotechnology using three innovative fluorescent polymers (FP-1, FP-2, and FP-3) encapsulated in niosomal carriers, combining therapy (chemotherapy and radiotherapy) with fluorescence imaging. These cargoes are assessed for their cytotoxic effects across three cancer cell lines (A549, MCF-7, and HOb), with further analysis to determine their capacity to augment the effects of radiotherapy using a Linear Accelerator (LINAC) at specific doses. Fluorescence microscopy is utilized to verify their uptake and localization in cancerous versus healthy cell lines. The results confirmed that these niosomal cargoes not only improved the antiproliferative effects of radiotherapy but also demonstrate the practical application of fluorescent polymers in in vitro imaging. This dual function underscores the importance of dose optimization to maximize therapeutic benefits while minimizing adverse effects, thereby enhancing the overall efficacy of cancer treatments.
在未来二十年，癌症预计将成为全球疾病相关死亡的首要原因，这突显了对个性化和适应性治疗策略的迫切需求。由于药物疗效的高度可变性和癌细胞产生耐药性的趋势，这些策略至关重要。本研究利用三种封装在脂质体载体中的创新荧光聚合物（FP-1、FP-2 和 FP-3），研究了治疗诊断纳米技术的潜力，将化疗和放疗与荧光成像相结合。评估了这些载药在三种癌细胞系（A549、MCF-7 和 HOb）中的细胞毒性作用，并进一步分析了它们在特定剂量下使用线性加速器（LINAC）增强放疗效果的能力。荧光显微镜用于验证它们在癌细胞与正常细胞系中的摄取和定位。结果证实，这些脂质体载药不仅提高了放疗的抗增殖作用，还证明了荧光聚合物在体外成像中的实际应用。这种双重功能强调了剂量优化的重要性，以最大限度地提高治疗效益，同时最小化不良反应，从而提高癌症治疗的整体效果。
